RIO DE JANEIRO, BRAZIL – The small US investment firm RA Capital Management made US$255 million (R$1.3 billion) in less than four weeks, all due to a bet on Novavax, company that has an advanced vaccine project against the novel coronavirus.
The Novavax vaccine began with experimental human trials against the novel coronavirus, placing it in a select group of pharmaceutical companies to be – relatively – close to developing a protection against Covid-19.
According to a report in The Wall Street Journal, RA Capital Management bought 7.5 percent of Novavax’s shares, which totaled 4.4 million shares and cost US$12 million on June 12th this year.
The American company’s shares rose 2,300 percent in 2020 alone. The last surge occurred on Tuesday, July 7th, when the US government invested US$1.6 billion in the company to develop and produce a vaccine against the novel coronavirus.
There is still no vaccine offering protection against Covid-19, but research developments have already led to billion-dollar investor gains, as evidenced by the case of RA Capital Management.
Source: Exame
More: Brazil news in English, every day from The Rio Times.
This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error
Brazil runoff, Sunday, October 25: When is the Brazil runoff election. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.